Japan Tobacco

Good afternoon. I'm Hiromasa Furukawa, CFO of JT Group. Thank you for joining us today for the JT Group's second quarter 2024 earnings briefings. I'll begin by explaining our six-month consolidated results for the fiscal year 2024. Please see slide 4. As shown on the slide, revenue and AOP increased both on the constant FX and on a reported basis. AOP at constant currency, our primary performance indicator, increased 2.7% year-on-year. This solid performance resulted mainly from the tobacco business where the robust pricing contributions outweigh the impacts of increased investment towards bloom, higher supply chain cost, and higher indirect cost such as labor cost. Higher profit in the processed food business also contributed to this performance. Regarding FX, essentially coming from the tobacco business, the impact on AOP at constant FX was unfavorable due to the depreciation of emerging market currencies and depreciation of cost-related currencies more than offsetting the positive impact of weaker yen. Operating profit increased 4.6% year-on-year due to the increase in AOP and a decrease in amortization of trademark rights among adjusted items. Profit increased 6.3% year-on-year driven by the increase in operating profit as well as lower financial costs. Finally, free cash flow increased by ¥24.9 billion to ¥179.8 billion. This increase was driven by the AOP growth as well as the improvement in working capital. Moving on to the results of each business segment. First, let's look at the volume results in the tobacco business. Please see slide 5. Total volume, combining sales of combustibles and RRP showed a strong performance in the first half of the year with a 2.0% increase year-on-year. In the combustible category, EMA cluster continued to drive volume growth. This strong performance was driven by the continued market share gains and volume momentum in margin countries, positive industry volume in most of the cluster, and ongoing growth in global travel retail, mainly in Asia. These factors resulted in an 1.7% year-on-year increase in combustible volume, offsetting headwinds resulting from lower combustible industry volume in Japan, the Philippines and the UK, as well as the business model change in Sudan. RRP volume increased significantly by 25.5% year-on-year, driven by an increase in HTS volume, our investment priority. In addition to the growth market share in HTS segment in Japan, volume growth was supported by the additional market where Plume was launched, particularly in the Western Europe cluster. Moving on to the financial performance of the tobacco business on slide 6, and more specifically, AOP. The first half of the year delivered a strong performance driven by the pricing contribution from several markets such as the Philippines, Russia, and the UK, resulting in AOP increase of 5.3% year-on-year at constant effects. While the total volume increased compared to the previous year, the financial contribution of this volume was negative to AOP. This is due to a lower geographic mix resulting from a higher volume composition from relatively lower margin market, mostly located in the IMA cluster. Additionally, the product mix was negatively affected mainly due to down trading in Japan and the Philippines. The robust pricing contribution was also partially offset by increased investment toward the accelerated geo-expansion of Bloom, higher supply chain costs, and higher indirect costs such as labor costs. The FX impact on ALP was negative, mainly due to the depreciation of certain emerging market currencies such as the Russian ruble and the appreciation of cost-related currencies such as the US dollar and the Swiss franc, more than offsetting the positive impact of a weaker yen. Slide 7 reviews the performance of the three clusters in the tobacco business. The graph on this slide shows year-on-year changes in total volume, core revenue, and AOP on a constant FX for each cluster. First, Asia. This cluster includes Japan, the Philippines, and Taiwan. The total volume decreased by 1.2% year-on-year, mainly due to the lower combustible industry volume in Japan, the Philippines and Taiwan, partially offset by market share gains in the Philippines and Taiwan and higher plume volume in Japan. Regarding financial results, the combination of negative volume contribution and negative product mix due to down trading in Japan and the Philippines, as well as higher supply chain cost, resulted in a decline in both revenue and profit, despite the solid pricing. Moving on to Western Europe. This cluster includes Italy, Spain, and the UK. Total volume decreased by 2.8% year-on-year despite market share gains in several markets, including Italy, and positive volume contribution from markets where Plume was launched. This decrease was mainly due to lower combustibles industry volume in several markets, particularly in France and the UK. Turning to financial results, revenue increased as pricing contributions in markets such as France, Germany, Spain and the UK offset the negative volume variance. However, increased investment towards plume and higher increased supply chain cost resulted in lower profit. Lastly, IMA. This cluster includes Romania, Russia, and Turkey. Despite impact from the business model change in Sudan, total volume increased by 5.1% year-on-year, driven by market share gains in several markets, volume growth in global travel retail, mainly in Asia, and favorable industry volume in several markets including Russia and Turkey. Regarding financial results, revenue and profit increased, the positive volume contributions and the strong pricing benefit in several markets, mainly in Russia, outweighed the increased investment toward prune and higher supply chain cost. Slide 8 describes the performance of the RRP category in the tobacco business. ROV volume increased by 25.5% year-on-year to 5.2 billion units. Plume is now available in 21 markets as of today. Japan continues to account for the majority of the volume and is now supported by the steady volume growth in markets outside Japan. In Japan, plume volume grew by approximately 36% year-on-year, outperforming the growth rate of the HTS industry, which we estimated at 15.1%. In addition, with the volume increase, RRP-related revenue increased by approximately 29% year-on-year. This steady growth aligns with our ambition to increase our RRP-related revenue by approximately 2.5 times by the end of 2026 compared to 2023.

On this slide, I will provide an update on the segment share trend of Plume and several markets. As shown in the graph, Plume market share in Japan and outside Japan is showing solid growth. In Japan, despite a very competitive landscape in HDS, the quality of our offering, combined with relevant marketing and promotion activities towards adult consumers, have led to an increase of segment share. In Slovakia and Spain, where Plume was launched in March and April this year, respectively, we have been gaining market share from the early stage of Plume's launch and are off to a good start. I would like to also highlight that JT's aggregated HTS share of segment in our key HTS markets, where Plume is available, has reached 8.2% in June. We are encouraged by these early estimates, putting us on track with our 2028 ambition to reach mid-teen HTS segment share. We acknowledge that it will take time to build a strong brand, but effective targeted promotions and marketing activities have been successful and have steadily increased the awareness of Plume. In addition, recognition, trial, and repeat are also showing good progress. Taste and experience of plume have been highly evaluated by consumers outperforming or matching competitor offerings. Next, I will explain the results of the pharmaceutical and processed food businesses. First, the pharmaceutical business. Revenue decreased by 3.6 billion yen due to the absence of one-time compensation gains from licensed compounds received in 2023, despite sales growth in the area of skin diseases and allergens at our consolidated subsidiary, Torii Pharmaceutical. due to revenue losses driven by non-recurring compensation gains from 2023 as well as higher R&D expenses We continue our efforts to expand the portfolio for future revenue and profit generation. A good example of these efforts is the announcement made on June 24 after we received manufacturing and marketing approval of V-Tama Cream 1% for the treatment of atopic dermatitis and plaque psoriasis in Japan. Moving to the processed food business. Revenue remained flat versus prior year, as the price revisions offset the impact of decrease in sales of household products and the discontinuation of some products as a result of portfolio optimization. AOP increased year-on-year, as the price revisions offset the higher raw material costs. From the next slide, I will guide you through our revised forecast for fiscal 2024. First, I will explain our full-year consolidated revised forecast. Revenue and AOP at constant FX and at reported basis have been revised upward. We have revised up our forecast for core revenue at constant currency by 20 billion yen as we now anticipate a 4.7% increase year-in-year. This increase reflects the robust business momentum in the tobacco business throughout the first half of the year, as well as the upward revision of revenue in the pharmaceutical and processed food businesses. For AOP at constant FX, we anticipate a 2.3% year-on-year increase, which represents an upward revision of 17 billion yen, driven by the revision of core revenue at constant FX. The revised forecast includes a weakening of the Japanese yen versus our initial guidance. As a result, the favorable FX impact on revenue is anticipated to expand, and the negative FX impact on ALP is anticipated to ease compared to the initial forecast. Consequently, revenue and AOP on a reported basis have been revised upward by 93 billion yen and 22 billion yen, respectively, from the initial forecast. We have revised up our forecast for operating profit by 12 billion yen, reflecting the revision of AOP more than offsetting the higher costs and adjusted items. Profit has been revised upward by 20 billion yen from the initial forecast, due to the upward revision of operating profit, as well as an improvement in financial costs. Finally, free cash flow has been revised upward by 16 billion yen due to the upward revision of AOP, as well as improvement in working capital, which more than offset the increase in capital expenditures. The following slides explain the revised forecast of each business. First, let's look at the volume forecast for the tobacco business. We continue to anticipate a decrease of approximately 1% to 0.5% year-on-year for the total volume, combining sales of combustibles and RRP, in line with our initial forecast. This reflects the upsides from the improved share in combustibles and the growth of RRP volume in the first half. However, this is offset by higher-than-expected combustibles industry volume contraction in key markets, namely in the Philippines and the UK, and downward revision of our shipment volume in Japan. Turning to the financials. We have revised upward our forecast for core revenue at constant currency by 15 billion yen as we now anticipate a 5.1% increase year-on-year versus 4.5% in our previous forecast. This increase reflects the strong pricing contribution in first half of the year, as well as the RRP revenue growth driven by the RRP volume increase. Next, for AOP at constant FX, we anticipate a 5.4% year-on-year increase versus 2% in our previous forecast, which represents an upward revision of 25 billion yen, resulting from the core revenue increase and contained costs. We expect certain supply chain costs being lower and also higher investment towards Plume compared to the initial forecast. We expect the FX impact to remain a headwind to AOP. However, due to the expected weaker Japanese yen, the extent of this impact is anticipated to be smaller than initially estimated. Specifically for the second half of the year, we expect a slowdown in total volume, mainly in our key markets. On the other hand, there was a one-time cost related to the renewal of RRP product in Japan in the second half of last year, meaning a higher cost base during this period. As a result, this year, the cost impact will be relatively moderate in the second half compared to the first half. Therefore, the gross rate of AOP at constant FX in the second half is expected to be at the same level as for staff in the second half. Pricing contribution is expected to be robust throughout the year. Slide 14 explains the revised forecast for the pharmaceutical and processed food businesses. The forecast for revenue in the pharmaceutical business has been revised upward by 4.5 billion yen from the initial forecast due to an expected increase in sales at Torii Pharmaceutical and an upward revision in overseas royalty income driven by the depreciation of the Japanese yen. AOP has been revised upward by 3 billion yen from the initial forecast due to the revenue revision as well as the management of SG&A expenses at Torii Pharmaceutical. Moving on to the processed food business. Revenue is revised upward by 0.5 billion yen from the initial forecast, incorporating the sales growth in the seasoning business. Forecast for AOP remains unchanged, as the improved revenue is expected to be offset by unfavorable FX impact. Finally, please see slide 16. we continue to deliver strong top-line growth, driven by solid pricing contribution in the tobacco business. This performance is also derived from the steady growth in HTS, our investment priority, fueling an accelerated contribution of the RRP category in both volume and revenue. The profit growth in the processed foods business also supported the group's profit growth. These strong first half results, coupled with the ongoing depreciation of the Japanese yen, have led us to revise upward our consolidated four-year forecasts from the top line to the bottom line. Finally, regarding shareholder returns. Based on the revised profit forecast, our payout ratio for fiscal year 2024 will be approximately 73%, which is in line with the boundaries set out in our shareholder return policy, which I have described in previous presentations. Consequently, we have not altered our forecast for the annual dividend from our initial projection of 194 yen per share. This concludes my presentation. Thank you very much for your attention. Thank you. Thank you, Mr. Furukawa. Now I'd like to start Q&A session. Let me introduce you the speakers who will answer your questions today. Hiromasa Furukawa, CFO of the JT Group, and Nobuya Kato, JTI Deputy CEO. Next, I will show you how to ask questions. We are afraid we don't accept questions in this English line. If you have any questions, please send an email to jt.ir at jt.com. We will introduce your question accordingly. Thank you for your understanding.

Now, we'll take the first question. Mr. Saji from Mizuho Securities, please. Thank you. I'd like to ask about the UK. In the second quarter, the volume was a bit tight. And originally, the combustible The market was expected to be down by about 7%, but in the first half it was down by about 17%, so a double-digit decline was marked. So I'd like to ask a question about affordability of tobacco in the UK. Initially, it was said that there would be some room for further pricing. But what do you think about that now? And also, your value segment, for example, fine cut, your share has been robust, but I think it has been declining a bit. So your position in the UK and also the strategy, the price strategy or the category strategy, I'd like to know the basics about your strategy. about the UK tobacco affordability and the room for the further pricing and also in the value categories share loss. Going forward, what will be the strategy will be described by Mr. Kato. I'm Kato. Thank you very much for your question, Mr. Sagi. As you said, the UK is volume down. 17% was marked in the first half, and it was rather a sizable one. And the industry volume declined. As you maybe know, in the 23 last year, there was the repeated tax hike, and also the pricing happened, and then the industry volume declined, and affordability worsened. And looking at the full year, you commented on that part as well. And as you mentioned, that the double-digit decline might be happening for the full year. And pricing strategy, whether we do have the further room or not, and the basic strategy, including a fine cut, how we're going to play out. In the United Kingdom, the first, the pricing, we are going to ensure the pricing. On the other hand, we are going to respond to the volume decline, and we need to strike the optimized balance to ensure the improvement of the profitability. That is a key point. and because sometimes that the pricing might deteriorate the volume to some extent but understanding that we like to take pricing and also sometimes in order to keep the share or the volume we might enhance the value categories so in the mid term we're going to ensure by striking the best balance Going forward, not only this year, but next year onward, that the most influential factor for the industry volume will be the tax hike. And as you know, as I said before, last year there was a repeated number of tax hikes. And then what will happen? Because of the change of the government, how the new government is going to address will make the great impact for the upcoming industry volume. And of course, we need to be watchful. And as I said before, we're going to ensure the improvement of the profitability in the midterm, and not only for the combustibles, but of course, the other tobacco categories are increasing in the UK and we are looking at those growths as well and category share although a bit low but HTS and prune launch has happened and also nicotine pouch is also growing in the UK and our nicotine pouch is also growing. and that is making the positive contribution for the profit. So putting all together, the tobacco portfolio, we'd like to make the further approach. Thank you. One confirmation, in Russia, result was good, but in the second quarter, in Western Europe, the profit was down to some extent, so I'd like to have one confirmation. Up to now, the pricing was able to offset the volume decline. And I'm going to go back to the previous strategy, because this market is very important. Thank you for your question. Western Europe, Q2, Quote on quote, there was some more deterioration, so how do you see that? What's your question, including the UK? I think that is a key point of your question. And not only in the UK, but in Western Europe cluster as a whole, the Q1 result was strong, or the decline was very small in terms of the year-on-year comparison. So I think that is one thing to look at. And as I said in the Q1 results meeting, Spain, Italy, France, there were the positive inventory adjustment, and that has affected the volume favorably. So Q2, quote-unquote, it seems that there was some decline. So I think that is one important factor. Understood. Thank you.